OPTIMA IPL

Treat the root cause: chronic inflammation

Optima IPL is a drug free, drop free light-based treatment, which targets the root causes – chronic inflammation.

Optima IPL treats periocular inflammatory conditions such as Rosacea and telangiectasia, which may lead to ocular surface conditions such as Dry Eye6,7. 80% of rosacea patients suffer from Meibomian Gland Dysfunction.

Optima IPL

STOP THE VICIOUS CYCLE
OF INFLAMMATION

icon

Reduces inflammatory mediators

Decreases the level of pro inflammatory mediators, progressing the inflammation3, 4

Abnormal Blood Vessels icon

Alleviates Abnormal Blood vessels

Destroys the abnormal blood vessels that are perpetuating the inflammation1,2

Decrease Demodex icon

Decreases Demodex

Decreases Demodex mites which are stimulating infection leading to inflammation5

ENERGY TO
EYE CARE

Uniquely designed for the periocular region

The Optima IPL is the next-generation IPL technology developed by Lumenis.
With every pulse of light, this first-of-its-kind, energy-based therapy works to
control the inflammatory process and to stop the vicious cycle of inflammation
Reducing the need for medications and providing long-lasting results.

Image
Friendly user interface for easy, convenient use
SapphireCool™ tip for safe and comfortable treatment
Small and large lightguides for ideal access and coverage
Expert Filters – tailored to the skin type and condition for optimized results
Specific presets for treatment of periocular conditions as well as additional skin indications.
Add on cart, for use in multiple locations

VISIT LUMENIS VISION BLOG TO LEARN FROM OUR EXPERTS

GO!

LUMENIS PATENTED
TECHNOLOGIES

Enables to treat with up to 20 J/cm2, gently and safely for maximum effectiveness

Optima IPL with OPT™

SAFETY
No spikes in energy The energy you choose is the energy you get

EFFICACY
Consistent level of energy in every pulse, throughout the pulse

Optima IPL SapphireCool™ chiller tip

Patented water cool tips: perfect fit for eye-care SapphireCool™ chiller tip allows to:

1. Reach higher levels of energy and achieve optimal results

2. Provide safe and comfortable treatment for the patient

3. Small tip for better access to eyelid area

ANTARES DRY EYE
DISEASE DIAGNOSTICS

Advanced, automated DED diagnostic and corneal topographer

icon

Quality

Accurate, reliable, reproducible and low intra-rater variability

icon

Speed

Fast examination process and results

icon

Comfortable

Offers patient comfort as well as physician ease of use

icon

Applications

Dry eye report, Meibography, Tear Breakup Time, Tear Meniscus, Topographer

antares device

WHAT ARE THE
EXPERTS SAYING?

Must have in the ophthalmic toolbox

Practice locator

FIND A PRACTICE
NEAR YOU

Find A Practice

OPTIMA IPL
SPECIFICATIONS

ExpertFilters

515 nm; 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755nm

Lightguides

15 x 35 mm; 8 x 15 mm

Fluence

Up to 35 J/cm2

Cooling

Continuous contact cooling

OPTIMA IPL FOR DRY EYE*

Visit Optima IPL site to learn about Dry eye Disease and how to treat it

*Not available in the US. Available in European Union CE, China, Australia, New Zealand, South Korea, Brazil, Hong Kong and Poland only

OPTIMA IPL brochures

WANT TO LEARN MORE?

Download Optima IPL & Dry Eye Antares kit

Get comprehensive information, detailed brochures and product reviewing videos here

Download Kit

Risk and warning (non-inclusive list): Treatment with M22 Optima IPL is contraindicated for patients with the following conditions in the treatment area: active infections, dysplastic nevi, tattoos, significant concurrent skin inflammation (excluding rosacea or acne), active cold sores, open lacerations, abrasions, and prolonged sun-exposure. Caution is advised for patients with a compromised immune system, coagulation disorders, photosensitivity, hormonal disorders, or a history of Herpes simplex near the treatment area. Patients eyes must be occluded with eye shields during the treatment.

1. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22; 2. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32; 3. Liu et
al. (2017) Am J Ophthalmol 183:81-90.; 4. Yin et al. (2018) Curr Eye Res 43(3):308-13; 5. Prieto et al. (2002) Lasers Surg Med 30(2):82-5; 6. De Paiva et al. (2006) Am J Ophthalmol 141(3):438-45; 7. Solomon et al. (2004) Ocul Surf 2(1):34-44;

*Antares is manufactured for Lumenis inc. by Costruzione Strumeni Oftalmici

PB-00001770 Rev A